Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG

Classement en actions #20278
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Prix de l'action
$8.32
Capitalisation boursière
$129.22M
Changement (1 jour)
1.59%
Changement (1 an)
65.41%
Pays
US
Échange Alpha Cognition Inc (ACOG)

Catégorie

Healthcare
EPS pour Alpha Cognition Inc (ACOG)
EPS au June 2026 TTM : $-0.40
Selon les derniers rapports financiers et le cours de l'action de Alpha Cognition Inc, l’EPS actuel de la société (TTM) est de $-0.40. À la fin de 2022, la société avait un EPS de $-0.18 une diminution par rapport à celui de 2021, qui était de $-0.37.
Historique de l'EPS de Alpha Cognition Inc de 2018 à 2026
EPS à la fin de chaque année
Année EPS Changez
2026 (TTM) $-0.40 166.67%
2023 $-0.15 -16.67%
2022 $-0.18 -51.35%
2021 $-0.37 -61.46%
2020 $-0.96 357.14%
2019 $-0.21 672.06%
2018 $-0.03 0.00%
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -4,430.00%
US
$-7.98 1,895.00%
US
$-5.29 1,222.50%
AU
- -
CH
$27.74 -7,035.00%
NL